Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Aristo Bio-Tech & Lifescience Ltd

Chemicals & Petrochemicals | Small Cap

Aristo Bio-Tech & Lifescience Ltd Health Insights
Health Score : 7.93Health Score : 7.93

Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Aristo Bio-Tech & Lifescience Ltd Health Insights
Health Score : 7.93Health Score : 7.93

Aristo Bio-Tech & Lifescience Ltd demonstrates a mixed financial performance. The company shows strong solvency and growth, driven by effective management of debt and impressive increases in revenue, operating profit, and EPS. Profitability metrics are also robust, supported by healthy gross profit and operating margins. However, liquidity is a concern, with ratios indicating potential difficulties in meeting short-term obligations. While efficiency ratios are generally average, there are notable strengths in asset turnover. The company's financial ratios reveal some weaknesses in earnings per share and book value per share, despite adequate capital expenditure. Overall, Aristo Bio-Tech showcases solid financial health, but needs to improve its liquidity position and financial metrics to ensure long-term stability and growth.

Latest Report

View All

The Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.


Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Undervalued

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Undervalued

P/E RATIO (TTM)

21.42

Undervalued

Industry Median

22.59

Undervalued
Neutral

Small Cap Median

21.70

Neutral

P/E RATIO

19.45

P/B RATIO

1.90

Neutral

Industry Median

1.76

Neutral
Neutral

Small Cap Median

1.77

Neutral

P/S RATIO

0.25

Highly Undervalued

Industry Median

0.89

Highly Undervalued
Highly Undervalued

Small Cap Median

0.88

Highly Undervalued

Others

Undervalued

PEG RATIO

0.61

Undervalued
Neutral

EV/EBITDA RATIO

8.49

Neutral

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹115.9 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

The company demonstrates strong growth across various metrics. The revenue growth rate is impressive, indicating successful expansion of sales. The operating profit growth rate is also robust, reflecting improved operational efficiency. Earnings per share (EPS) growth is significant, showing enhanced profitability for shareholders. The asset growth rate is healthy, reflecting strategic investments and expansion. The net income growth rate is also substantial, indicating improved overall profitability. These factors collectively suggest that the company is experiencing strong and sustainable growth.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate-0.631.3312.3929.814.47
Operating Profit Growth Rate2580-11.1112.577.78
Earnings Per Share (EPS) Growth-2.78149.059.564.0177.01
Asset Growth Rate-4.9429.872711.029.93
Net Income Growth Rate03000075
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 3.60

The company's financial ratios reveal certain weaknesses. The adjusted earnings per share and book value per share are low, indicating potential concerns about profitability and shareholder value. The cash earnings per share is also relatively low. However, capital expenditures are adequate, reflecting ongoing investments in the company's growth and infrastructure. These factors collectively suggest that the company needs to improve its earnings and shareholder value to enhance its financial performance.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
PoorDividend Per Share (DPS)Poor
GoodCapital Expenditures (CapEx)Good
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)25.715.715.7110
Cash Earnings Per Share (Cash EPS)48.578.571014.29
Book Value Per Share3042.8648.5754.2964.29
Dividend Per Share (DPS)00.260.40.480.63
Capital Expenditures (CapEx)3.12.56.54.93
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 9.60

The company's profitability ratios are generally strong. The gross profit margin is healthy, indicating effective cost management. The return on capital employed (ROCE) is also robust, reflecting efficient use of capital to generate profits. The return on equity (ROE) is substantial, showing good returns for shareholders. The return on assets (ROA) is moderate, suggesting adequate asset utilization. The operating margin is healthy, reflecting efficient operational performance. The net margin is also robust, indicating good overall profitability. These factors collectively suggest that the company is effectively managing its profitability.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
AverageReturn on Assets (ROA)Average
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin2.413.212.451.893.57
Return on Capital Employed (ROCE)1116131220
Return on Equity (ROE)6.6713.3311.7610.5315.56
Return on Assets (ROA)6.4996.36.3810.32
Operating Margin3.014.133.272.834.4
Net Margin0.61.831.631.261.92
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 6.33

The company's efficiency ratios present a mixed picture. The fixed asset turnover ratio is strong, indicating effective utilization of fixed assets to generate revenue. However, the inventory turnover ratio and receivables turnover ratio are average, suggesting there may be room for improvement in managing inventory and collecting receivables. The days sales in inventory ratio is also average, indicating that the company holds inventory for a moderate period. The receivable days are slightly elevated, suggesting potential challenges in collecting payments promptly. The capital turnover ratio is average, reflecting moderate efficiency in using capital to generate revenue.

ExcellentFixed Asset Turnover RatioExcellent
AverageInventory Turnover RatioAverage
AverageReceivables Turnover RatioAverage
AverageDays Sales in Inventory RatioAverage
WeakReceivable DaysWeak
AverageCapital Turnover RatioAverage
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio11.8613.6211.1413.2515.17
Inventory Turnover Ratio5.797.676.77.176.38
Receivables Turnover Ratio5.035.594.85.636.56
Days Sales in Inventory Ratio63.0447.5954.4850.9157.21
Receivable Days72.5665.376.0464.8355.64
Capital Turnover Ratio6.365.435.576.976.92
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 8.80

The company's coverage ratios indicate a strong ability to meet its interest and dividend obligations. The interest coverage ratio suggests that the company can comfortably cover its interest expenses with its earnings. The equity dividend coverage ratio is also high, indicating that the company has ample earnings to cover its dividend payments. These factors collectively suggest that the company has a strong capacity to service its debt and provide returns to its shareholders.

GoodInterest Coverage RatioGood
ExcellentEquity Dividend Coverage RatioExcellent
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio22.673.53.53.5
Equity Dividend Coverage Ratio2014.2912.516.67
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company exhibits strong solvency, indicating a solid financial foundation. A low debt ratio and debt-to-equity ratio suggest conservative use of leverage. A high equity ratio further supports the company's financial stability. The low debt-to-asset ratio confirms that a small portion of the company's assets are financed by debt. These factors collectively suggest that the company has a strong capacity to meet its long-term obligations and manage its financial risks effectively.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.430.250.230.170.14
Debt to Equity Ratio0.750.330.30.20.16
Equity Ratio0.570.750.770.830.86
Debt To Asset Ratio0.140.10.080.050.05
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 4.26

The company's liquidity position reveals certain vulnerabilities. While the quick ratio suggests an ability to meet immediate liabilities, this is offset by a low cash ratio, indicating limited availability of liquid assets. The current ratio is below the ideal threshold, suggesting potential difficulties in covering short-term obligations. The operating cash flow ratio needs improvement to ensure alignment with short-term funding needs. These factors collectively indicate that the company may face liquidity challenges, requiring careful management of working capital.

WeakCurrent RatioWeak
AverageQuick RatioAverage
PoorCash RatioPoor
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio1.231.41.261.231.27
Quick Ratio0.760.880.790.740.66
Cash Ratio00.030.010.010.03
Operating Cash Flow Ratio0.14-0.050.10.110.08
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 4 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Aristo Bio-Tech & Lifescience Ltd7.9319.45Undervalued16.0010.557.00
2Ambey Laboratories Ltd7.0819.30Neutral10.001.92N/A
3Crop Life Science Ltd6.8711.37Neutral18.004.086.00
Management Assessment Summary
OrangeBalanced Management

The management effectiveness of Aristo Bio-Tech & Lifescience Ltd shows a mixed performance. The company exhibits strong sales growth and increasing dividend payouts, indicating positive financial development. However, there are concerns regarding profitability and capital efficiency, with inconsistent operating profit margins and a low ROCE. Despite stable promoter holding, the fluctuations in financial performance suggest areas where management could enhance operational efficiency and capital allocation.

Category Metric Value Assessment
PROS Sales Growth TTM 30% Strong sales growth indicates market competitiveness.
Dividend Payout (Mar 2025) 8% Increasing dividend payout suggests management's confidence in future earnings.
CONS OPM (Mar 2025) 1% Low OPM raises concerns about operational efficiency.
ROCE (Mar 2024) 13% Low ROCE signals inefficient capital allocation.
AverageFinancial Performance & GrowthAverage
AverageCapital Efficiency & ReturnsAverage
GoodFinancial Health & PrudenceGood
AverageStrategic & Operational IndicatorsAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Strategic & Operational Indicators

Risk Assessment Summary
OrangeBalanced Risk

The risk assessment for Aristo Bio-Tech & Lifescience Ltd indicates moderate risk. The company's trends in sales growth and profitability suggest some operational risks. The absence of data on off-balance sheet exposures and contingent liabilities limits a full assessment, suggesting a need for further investigation into these areas.

PoorOff-balance sheet exposure quantificationPoor
PoorContingent liability evaluationPoor
PoorSegment performance volatilityPoor
01.

Off-balance sheet exposure quantification

02.

Contingent liability evaluation

03.

Segment performance volatility

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe